Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID study of etripamil nasal spray for termination of spontaneous PSVT episodes
2018-000308-41Phase 3Completed
- Sponsor
- Milestone Pharmaceuticals
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in paroxysmal supraventricular tachycardia (PSVT) comparing Etripamil nasal spray with Placebo nasal spray (2 arms). Primary endpoint: Primary efficacy endpoint. Started Oct 2020; status: completed.
02
Drugs
etripamil
03
Conditions
paroxysmal supraventricular tachycardia (PSVT)
Beyond the preview
Go deeper on 2018-000308-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000308-41.